Low dose colchicine use in familial Mediterranean fever patients whose disease is under control

Sogol Sadri; Emine Aşçı; Gamze Ergün; Ozan Cemal İçaçan; Selda Çelik; Cemal Bes; Nilüfer Alpay Kanıtez

doi:10.4274/raed.galenos.2020.69885

ABSTRACT

Conclusion:

In real life, a significant number of AAA patients reduce the dose of colchicine. The subclinical inflammation rate is higher in these patients. Long-term follow-up results are needed for the risk of amyloidosis.

Results:

A total of 114 FMF patients [76 (67%) female and 38 (33%) male] were included in this study. It was determined that the average colchicine dose of 58 (51%) patients was low dose (<1.5 mg/d). The proportion of patients with subclinical inflammation in the low-dose colchicine group was statistically significantly higher than the standard dose colchicine group (34% and 16% respectively, p=0.031).

Methods:

International severity scoring system score (ISSF) for FMF was calculated to determine the severity of disease in FMF patients admitted to our clinic. FMF patients, those have an ISSF score ≤2, were divided into two groups regarding to their average daily colchicine dose as low dose group (<1.5 mg per/day) and standart dose group (≥1.5 mg per/day).

Objective:

The initial dose of colchicine recommended for the treatment of familial Mediterranean fever (FMF) is 1-1.5 mg/day in adults. The aim of this study is to identify FMF patients with mild or controlled disease, who can reduce colchicine doses.

Keywords:

Familial Mediterranean fever, low dose colchicine, subclinical inflammation

References

Toplak N, Frenkel J, Ozen S, et al. Paediatric Rheumatology International Trials Organisation (PRINTO), Eurotraps and Eurofever Projects. An international registry on autoinflammatory diseases: the Eurofever experience. Ann Rheum Dis 2012;71:1177-82.

Ozen S, Demirkaya E, Erer B, et al. Eular recommendations for the management of familia Mediterranean fever. Ann Rheum Dis 2016;75:644-51.

Livneh A, Langevitz P, Zemer D, et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 1997;40:1879-85.

Stankovic Stojanovic K, Hentgen V, et al. Concordance between CRP and SAA in familial Mediterranean fever during attack-free period: A study of 218 patients. Clin Biochem 2017;50:206-9.

Demirkaya E, Acikel C, Hashkes, et al. FMF Arthritis Vasculitis and Orphan disease Resarch in pediatric rheumatology (FAVOR). Development and initial validation of international severity sc oring system for familial Mediterranean fever (ISSF). Ann Rheum Dis 2016;75:1051-6.

Tunca M, Akar S, Onen F, et al. Turkish FMF Study Group. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore) 2005;84:1-11.

Üreten K, Gönülalan G, Akbal E, et al. Demographic, clinical and mutational characteristics of Turkish familial Mediterranean fever patients: results of a single center in Central Anatolia. Rheumatol Int 2010;30:911-5.

Mor A, Shinar Y, Zaks N, et al. Evaluation of disease severity in familial Mediterranean fever. Semin Arthritis Rheum 2005;35:57-64.

Ben-Zvi I, Krichely-Vachdi T, Feld O, Lidar M, Kivity S, Livneh A. Colchicine-free remission in familial Mediterranean fever: featuring a unique subset of the disease-a case control study. Orphanet J Rare Dis 2014;9:9-3.

Gershoni-Baruch R, Brik R, Zacks N, Shinawi M, Lidar M, Livaneh A. The contribution of genotypes at the MEFV and SAA1 loci to amyloidosis and disease severity in patients with familial Mediterranean fever. Arthritis Rheum 2003;48:1149-55.

Knieper AM, Klotsche J, Lainka E, et al. Familial Mediterraneanfever in children and adolescents: factors for colchicine dosage and predicting parameters for dose increase. Rheumatology (Oxford) 2017;56:1597-1606.

La Regina M, Ben-Chetrit E, Gasparyan AY, Livaneh A, Ozdogan H, Manna R. Current trends in colchicine treatment in familial Mediterranean fever. Clin Exp Rheumatol 2013;31:41-6.